An Open-Label Clinical Pharmacology Study of Brentuximab Vedotin (SGN-35) in Patients With CD30-Positive Hematologic Malignancies: CYP3A4 Drug-Drug Interactions, Excretion, and Special Populations
Interventional
Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Midazolam blood concentrations +/- brentuximab vedotin
3 weeks
Yes
Laurie Grove, PA-C
Study Director
Seattle Genetics, Inc.
United States: Food and Drug Administration
SGN35-008
NCT01026415
December 2009
December 2013
Name | Location |
---|---|
Hackensack University Medical Center | Hackensack, New Jersey 07601 |
City of Hope | Duarte, California 91010 |
NYU Clinical Cancer Center | New York, New York 10016 |
Colorado Blood Cancer Institute | Denver, Colorado 80218 |
Karmanos Cancer Institute / Wayne State University | Detroit, Michigan 48201 |
St. Francis Medical Group Oncology & Hematology Specialists | Indianapolis, Indiana 46237 |
Seattle Cancer Care Alliance / University of Washington Medical Center | Seattle, Washington 98109 |